• Real Time Chart Real Time Chart
  • Stock Profile Stock Profile
  • Balance Sheet

  • Symbol Info Symbol Info
  • Symbol Over View Symbol Over View
  • Technical Analysis Technical Analysis

URGN stock profile

UroGen Pharma Ltd Company Profile

Urogen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.

Company information

  • Company Name UroGen Pharma Ltd
  • Industry Pharmaceutical Preparation Manufacturing
  • CEO Elizabeth Barrett
  • Security Name UroGen Pharma Ltd
  • Sector Manufacturing
  • Employees 195
  • Exchange NASDAQ

CEO Compensation

  • Name Ron Bentsur
  • Location New York, NY
  • Symbol URGN
  • Salary 610200
  • OptionAwards 1739588
  • OtherComp 3266324
  • Total 5950112
  • PensionAndDeferred 0
  • Exchange
  • StockAwards 0
  • Bonus 0
  • Year 2018

Peers

  • OVAT-CA
  • OVID
  • OVIT
  • OYST

Top Executives

  • Entity Name
  • Position
  • Report Date
  • Belldegrun Arie
    10000
    2022-06-10
  • BUTITTA CYNTHIA M
    10000
    2022-06-10
  • Cohen Fred E
    10000
    2022-06-10
  • Holden Stuart
    10000
    2022-06-10
  • Nussbaum Ran
    3183
    2022-06-10
  • Schoenberg Mark
    1500
    2022-05-03
  • Kim Dong
    2022-03-29